Filana Therapeutics, Inc. (FLNA)
NASDAQ:FLNA
Top Page
Filana Therapeutics
(NASDAQ:FLNA)
Select Model
Select Model
Rating:44Neutral
Price Target:
$1.50
▼(-29.25% Downside)
Action:ReiteratedDate:03/13/26
The score is primarily held back by weak financial performance (no revenue, ongoing losses and cash burn, and shrinking equity/assets), with additional pressure from bearish technicals (price below key moving averages and negative MACD). Valuation is only slightly supportive because a negative P/E reflects losses and there is no dividend yield provided.
Positive Factors
Low Leverage
Near-zero debt materially reduces insolvency and interest burden risk for a cash-burning biotech. This durable balance-sheet strength preserves strategic optionality, making it easier to pursue partnerships, licensing, or targeted financings without immediate debt service constraints over the next several months.
Negative Factors
Zero Revenue Base
Absence of product or recurring operating revenue forces reliance on external financing or partnerships to fund operations. That structural dependence increases execution risk, makes R&D timelines sensitive to fundraising cycles, and can lead to dilution or program delays over the coming months if cash is insufficient.
Read all positive and negative factors
Positive Factors
Negative Factors
Low Leverage
Near-zero debt materially reduces insolvency and interest burden risk for a cash-burning biotech. This durable balance-sheet strength preserves strategic optionality, making it easier to pursue partnerships, licensing, or targeted financings without immediate debt service constraints over the next several months.
Read all positive factors
Filana Therapeutics (FLNA) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$83.57M
Dividend YieldN/A
Average Volume (3M)623.81K
Price to Earnings (P/E)―
Beta (1Y)0.93
Revenue GrowthN/A
EPS Growth-505.96%
CountryUS
Employees20
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.26
Shares Outstanding48,307,896
10 Day Avg. Volume367,881
30 Day Avg. Volume623,814
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)1.33
Price to Sales (P/S)0.00
P/FCF Ratio-3.02
Enterprise Value/Market Cap-0.14
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit32.51
Enterprise Value/Ebitda0.24
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-1.22
Revenue Forecast (FY)N/A
Filana Therapeutics Business Overview & Revenue Model
Company Description
Filana Therapeutics, Inc. engages in the development of novel drugs and diagnostics. It focuses on developing product candidates intended for the treatment of Alzheimer’s disease, including PTI-125 and PTI-125Dx. The company was founded by Remi Ba...
How the Company Makes Money
As a clinical-stage biotechnology company, Cassava Sciences has historically not had recurring commercial revenue from product sales because it does not have an FDA-approved product marketed for sale. Its cash inflows have primarily come from fina...
Filana Therapeutics Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
28
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -936.00K | 0.00 | -89.42M | -68.03M | 0.00 |
| EBITDA | -94.45M | -141.15M | -104.43M | -78.72M | -32.33M |
| Net Income | -90.97M | -24.34M | -97.22M | -76.25M | -32.38M |
Balance Sheet | |||||
| Total Assets | 118.36M | 157.53M | 151.66M | 234.83M | 266.78M |
| Cash, Cash Equivalents and Short-Term Investments | 95.50M | 128.57M | 121.14M | 201.01M | 233.44M |
| Total Debt | 0.00 | 0.00 | 0.00 | 139.00K | 236.00K |
| Total Liabilities | 43.95M | 11.83M | 14.20M | 7.29M | 12.87M |
| Stockholders Equity | 74.40M | 145.70M | 137.47M | 227.54M | 253.91M |
Cash Flow | |||||
| Free Cash Flow | -32.83M | -117.03M | -82.44M | -80.23M | -52.41M |
| Operating Cash Flow | -32.25M | -116.93M | -82.03M | -77.51M | -30.20M |
| Investing Cash Flow | -581.00K | -103.00K | -414.00K | -2.71M | -22.21M |
| Financing Cash Flow | -239.00K | 124.47M | 2.56M | 47.80M | 192.34M |
Filana Therapeutics Technical Analysis
Negative
2.12
Price Trends
2.03
Negative
2.33
Negative
2.49
Negative
Market Momentum
-0.12
Positive
40.25
Neutral
33.33
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FLNA, the sentiment is Negative. The current price of 2.12 is above the 20-day moving average (MA) of 1.89, above the 50-day MA of 2.03, and below the 200-day MA of 2.49, indicating a bearish trend. The MACD of -0.12 indicates Positive momentum. The RSI at 40.25 is Neutral, neither overbought nor oversold. The STOCH value of 33.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for FLNA.
Filana Therapeutics Risk Analysis
Filana Therapeutics disclosed 52 risk factors in its most recent earnings report. Filana Therapeutics reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Filana Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $165.38M | -3.23 | -90.51% | ― | -17.87% | 14.42% | |
50 Neutral | $77.56M | -8.98 | -109.73% | ― | ― | 50.39% | |
47 Neutral | $232.08M | -2.32 | -162.49% | ― | ― | 5.51% | |
44 Neutral | $83.57M | -1.09 | -97.94% | ― | ― | -505.96% | |
43 Neutral | $88.86M | -2.15 | 13.30% | ― | 448.44% | ― | |
| ― | $85.50M | -9.85 | -65.55% | ― | ― | 11.78% |
* Healthcare Sector Average
FLNA
Filana Therapeutics
1.73
0.42
32.06%
CDXS
Codexis
1.82
-0.24
-11.44%
MCRB
Seres Therapeutics
9.27
-2.18
-19.03%
ANIX
Anixa Biosciences
2.55
0.06
2.41%
CGTX
Cognition Therapeutics
0.87
0.52
148.00%
CAMP
CAMP4 Therapeutics Corporation
4.47
1.87
71.92%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.